LMO2 CRISPR/Cas9 KO Plasmid (m): sc-421447
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LMO2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the LMO2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LMO2 Antibody (1A9-1): sc-65736
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LMO2 CRISPR/Cas9 KO Plasmid (m) | sc-421447 | 20 µg | $397.00 |
Overview
Lmo2 encodes LIM domain only 2 (LMO2), a nuclear adaptor protein that assembles multi-protein transcriptional complexes controlling lineage specification and differentiation, particularly within hematopoietic and endothelial compartments. By bridging DNA-binding transcription factors and cofactors, LMO2 influences programs tied to stem/progenitor maintenance, angiogenic gene expression, and erythroid development. Dysregulated LMO2 expression or altered complex composition is linked to abnormal hematopoiesis and oncogenic transcriptional states, making it a frequent target in studies of leukemogenesis and vascular biology. Mouse Lmo2 models are therefore widely used to dissect transcriptional network architecture, enhancer-dependent regulation, and developmental fate decisions.
LMO2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Lmo2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Lmo2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Lmo2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish LMO2 protein expression.
This CRISPR knockout system enables efficient generation of Lmo2-deficient cell models for investigation of LMO2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Lmo2 exon(s) critical for LMO2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Lmo2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by LMO2 CRISPR/Cas9 KO Plasmid (m) and LMO2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Lmo2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by LMO2 HDR Plasmid (m) and LMO2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Lmo2 homology arms to support homology-directed repair at defined Lmo2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.